Search

Author/Creator Spriggs, D. R.

1. Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Issue 4 (1st June 2005)

Authors:
Kavanagh, J. J.; Gershenson, D. M.; Choi, H.; Lewis, L.; Patel, K.; Brown, G. L.; Garcia, A.; Spriggs, D. R.
Journal:
International journal of gynecological cancer
Issue:
Volume 15:Issue 4(2005)
Page Start:
593
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Issue 1 (1st January 2007)

Authors:
Sovak, M. A.; Dupont, J.; Hensley, M. L.; Ishill, N.; Gerst, S.; Abu-Rustum, N.; Anderson, S.; Barakat, R.; Konner, J.; Poyner, E.; Sabbatini, P.; Spriggs, D. R.; Aghajanian, C.
Journal:
International journal of gynecological cancer
Issue:
Volume 17:Issue 1(2007)
Page Start:
197
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗